CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts

Company Performance - CRISPR Therapeutics AG's stock closed at $42.94, reflecting a +2.02% increase from the previous day, outperforming the S&P 500's gain of 0.55% [1] - Over the past month, the company's shares have appreciated by 11.97%, significantly exceeding the Medical sector's gain of 3.49% and the S&P 500's gain of 6.29% [1] Upcoming Earnings Disclosure - The company is projected to report earnings of -$1.54 per share, indicating a year-over-year decline of 3.36% [2] - Revenue is expected to be $5.89 million, representing a substantial increase of 1032.88% compared to the same quarter last year [2] Annual Forecast - For the entire year, the Zacks Consensus Estimates predict earnings of -$5.54 per share and revenue of $39.95 million, reflecting changes of -27.65% and +7.06% respectively from the previous year [3] Analyst Estimates and Market Sentiment - Recent modifications to analyst estimates for CRISPR Therapeutics AG are crucial as they reflect short-term business trends [4] - Positive estimate revisions are viewed as a sign of optimism regarding the company's business outlook [4] Zacks Rank and Industry Performance - The Zacks Rank system, which evaluates estimate changes, currently ranks CRISPR Therapeutics AG as 3 (Hold) [6] - The Medical - Biomedical and Genetics industry, to which the company belongs, has a Zacks Industry Rank of 76, placing it in the top 31% of over 250 industries [7]